Pivotal Therapeutics Inc  

(Public, CNSX:PVO)   Watch this stock  
Find more results for PVO
0.000 (0.00%)
Apr 17 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range 0.15 - 0.19
52 week 0.00 - 0.24
Open 0.17
Vol. 6,500.00
Mkt cap 17.46M
P/E     -
Div/yield     -
EPS -0.04
Shares 91.92M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -809.86% -3861.15%
Operating margin -809.86% -3861.15%
EBITD margin - -3808.74%
Return on average assets -123.52% -140.72%
Return on average equity -558.69% -176.67%
CDP Score - -


Unit 10, 81 Zenway Blvd
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)

Website links


Pivotal Therapeutics, Inc. is a Canada-based pharmaceutical company with a focus on cardiovascular health. The Company offers VASCAZENTM, is a prescription grade, ultra-pure Omega 3 fatty acid for the dietary management of cardiovascular disease in patients manifesting an Omega 3 fatty acid deficiency. VASCAZENTM is manufactured according to FDA (Food and Drug Administration) current Good Manufacturing Practices (cGMP) and each capsule of VASCAZENTM provides 680 mg of Eicosapentaenoic (EPA) and 110 mg of Eicosapentaenoic (EPA), for oral administration.

Officers and directors

George Jackowski Ph.D. Chairman of the Board, Chief Scientific Officer
Rachelle MacSweeney President, Director
Eugene G. Bortoluzzi Chief Executive Officer, Chief Financial Officer, Director
James Connolly Director
John P. Nicholson Jr. Director
James J. Carey Independent Director
John S. Gebhardt Independent Director
Age: 65
Giuseppe Simeone Independent Director